Ipsen SA CEO David Loew has put up a stout defence of the company's ultra-rare bone disease therapy palovarotene which, despite a pretty precarious history, is set to be filed with regulators early next year.
The French drugmaker got hold of palovarotene for fibrodysplasia ossificans progressive (FOP) in February 2019 through the acquisition of Canadian...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?